Company Description
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore.
Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury.
It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore.
The company was incorporated in 2018 and is headquartered in Singapore.
| Country | Singapore |
| Founded | 2018 |
| IPO Date | Apr 14, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Wee Kiat Tan |
Contact Details
Address: 1 Commonwealth Lane, No. 08-22 Singapore, 149544 Singapore | |
| Phone | 65 6250 7738 |
| Website | w2.cytomed.sg |
Stock Details
| Ticker Symbol | GDTC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | SGD |
| IPO Price | $4.00 |
| CIK Code | 0001873093 |
| ISIN Number | SGXZ17669631 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Wee Kiat Tan Ph.D. | Co-Chief Executive Officer, Chief Operating Officer and Director |
| Chee Kong Choo | Executive Chairman |
| Dr. Jieming Zeng M.D., Ph.D. | Chief Scientific and Medical Officer and Director |
| Yvonne Goh | Chief Financial Officer |
| Dr. Tien Wee Luk M.D. | Chief Clinical Officer |
| Yoong Ying Tan | Chief Corporate Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 5, 2024 | 6-K | Report of foreign issuer |
| Nov 20, 2024 | 6-K | Report of foreign issuer |
| Nov 4, 2024 | 144 | Filing |
| Oct 7, 2024 | 6-K | Report of foreign issuer |
| Oct 3, 2024 | 6-K | Report of foreign issuer |
| Sep 30, 2024 | 6-K | Report of foreign issuer |
| Jun 24, 2024 | 6-K/A | Filing |
| Jun 20, 2024 | 6-K | Report of foreign issuer |
| May 24, 2024 | 6-K | Report of foreign issuer |
| May 23, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |